Avila, C., A. C. Holloway, M. K. Hahn, K. M. Morrison, M. Restivo, R. Anglin, and V. H. Taylor. 2015. An overview of links between obesity and mental health. Current Obesity Reports 4(3):303–310.

Barnes, H. V. 1975. Physical growth and development during puberty. Medical Clinics of North America 59(6):1305–1317.

Beamish, A. J., E. R. Harper, K. Järvholm, A. Janson, and T. Olbers. 2023. Long-term outcomes following adolescent metabolic and bariatric surgery. Journal of Clinical Endocrinology & Metabolism 108(9):2184–2192.

Börjeson, M. 1976. The aetiology of obesity in children. A study of 101 twin pairs. Acta Paediatrica Scandinavica 65(3):279–287.

Bruno, C. D., J. S. Harmatz, S. X. Duan, Q. Zhang, C. R. Chow, and D. J. Greenblatt. 2021. Effect of lipophilicity on drug distribution and elimination: Influence of obesity. British Journal of Clinical Pharmacology 87(8):3197–3205.

Bruno, C. D., A. Elmokadem, C. Housand, E. B. Jordie, C. R. Chow, T. P. Laughren, and D. J. Greenblatt. 2022. Impact of obesity on brexpiprazole pharmacokinetics: Proposal for improved initiation of treatment. Journal of Clinical Psychopharmacology 62(1):55–65.

Cardel, M. I., F. A. Newsome, R. L. Pearl, K. M. Ross, J. R. Dillard, D. R. Miller, J. F. Hayes, D. Wilfley, P. K. Keel, E. J. Dhurandhar, and K. N. Balantekin. 2022. Patient-centered care for obesity: How health care providers can treat obesity while actively addressing weight stigma and eating disorder risk. Journal of the Academy of Nutrition and Dietetics 122(6):1089–1098.

CDC (Centers for Disease Control and Prevention). 2000. CDC growth charts: United States. http://www.cdc.gov/growthcharts/ (accessed March 19, 2024).

CDC. 2008. Behavioral risk factor surveillance system survey data. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. https://www.cdc.gov/brfss/annual_data/annual_2008.htm (accessed March 20, 2024).

CDC. 2020. Youth Risk Behavior Survey questionnaire. https://www.cdc.gov/yrbs/ (accessed March 19, 2024).

CDER (Center for Drug Evaluation and Research). 2007. Developing products for weight management revision 1 (FDA-2007-D-0435). U.S. Food and Drug Administration. https://www.fda.gov/media/71252/download (accessed March 19, 2024).

CDER. 2018a. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: Developing drugs for treatment (FDA-2018-D-3632). U.S. Food and Drug Administration. https://www.fda.gov/media/119044/download (accessed March 19, 2024).

CDER. 2018b. Anthrax: Developing drugs for prophylaxis of inhalational anthrax guidance for industry (FDA-2016-D-0412). U.S. Food and Drug Administration. https://www.fda.gov/media/71320/download (accessed March 19, 2024).

CDER. 2019. Establishing effectiveness and safety for hormonal drug products intended to prevent pregnancy guidance for industry (FDA-2019-D-2153). U.S. Food and Drug Administration. https://www.fda.gov/media/128792/download (accessed March 19, 2024).

CDER. 2022. General clinical pharmacology considerations for pediatric studies of drugs, including biological products (FDA-2013-D-1275). U.S. Food and Drug Administration. https://www.fda.gov/media/90358/download (accessed March 19, 2024).

CDER and CBER (Center for Biologics Evaluation and Research). 2020. Enhancing the diversity of clinical trial populations—Eligibility criteria, enrollment practices, and trial designs guidance for industry. (FDA-2019-D-1264). U.S. Food and Drug Administration. https://www.fda.gov/media/127712/download (accessed March 19, 2024).

CDER and CBER. 2021. Development of anti-infective drug products for the pediatric population (FDA-2020-D-1518). U.S. Food and Drug Administration. https://www.fda.gov/media/139586/download (accessed March 19, 2024).

Chanoine, J.-P., S. Hampl, C. Jensen, M. Boldrin, and J. Hauptman. 2005. Effect of orlistat on weight and body composition in obese adolescents: A randomized controlled trial. JAMA 293(23):2873–2883.

Chow, C. R., J. S. Harmatz, M. J. Ryan, and D. J. Greenblatt. 2018. Persistence of a posaconazole-mediated drug–drug interaction with ranolazine after cessation of posaconazole administration: Impact of obesity and implications for patient safety. Journal of Clinical Psychopharmacology 58(11):1436–1442.

Christoffersen, B. Ø., G. Sanchez-Delgado, L. M. John, D. H. Ryan, K. Raun, and E. Ravussin. 2022. Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity 30(4):841–857.

Conmy, A. B., C. Peters, N. De Lew, and B. D. Sommers. 2023. Children’s health coverage trends: Gains in 2020–2022 reverse previous coverage losses (Issue Brief No. HP-2023–07). Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. https://aspe.hhs.gov/reports/childrens-health-coverage-trends (accessed March 20, 2024).

Cooper, D. M., M. A. Rothstein, A. Amin, J. D. Hirsch, and E. Cooper. 2023. Unintended consequences of glucagon-like peptide-1 receptor agonists medications in children and adolescents: A call to action. Journal of Clinical and Translational Science 7(1):e184.

Davis, S. R., C. Castelo-Branco, P. Chedraui, M. A. Lumsden, R. E. Nappi, D. Shah, and P. Villaseca. 2012. Understanding weight gain at menopause. Climacteric 15(5):419–429.

Decker, K. M., J. Reiter-Purtill, C. M. Bejarano, A. B. Goldschmidt, J. E. Mitchell, T. M. Jenkins, M. Helmrath, T. H. Inge, M. P. Michalsky, and M. H. Zeller. 2022. Psychosocial predictors of problematic eating in young adults who underwent adolescent bariatric surgery. Obesity Science & Practice 8(5):545–555.

Enebo, L. B., K. K. Berthelsen, M. Kankam, M. T. Lund, D. M. Rubino, A. Satylganova, and D. C. W. Lau. 2021. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: A randomised, controlled, phase 1b trial. The Lancet 397(10286): 1736–1748.

Epstein, L. H., D. E. Wilfley, C. Kilanowski, T. Quattrin, S. R. Cook, I. U. Eneli, N. Geller, D. Lew, M. Wallendorf, P. Dore, R. A. Paluch, and K. B. Schechtman. 2023. Family-based behavioral treatment for childhood obesity implemented in pediatric primary care: A randomized clinical trial. JAMA 329(22):1947–1956.

FDA (U.S. Food and Drug Administration). 2014. Clinical briefing document: Endocrinologic and Metabolic Drugs Advisory Committee meeting (NDA 206321). https://web.archive.org/web/20161024141110/http:/www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM413317.pdf (accessed March 19, 2024).

Fitch, A. 2021. Better together: Combination therapy for optimal obesity therapy [Conference presentation]. OMA 2021 Fall Convention, Chicago, Illinois, United States. https://academy.obesitymedicine.org/content/better-together-exploring-combination-therapies-obesity-management-recorded (accessed March 19, 2024).

Fontaine, K. R., D. T. Redden, C. Wang, A. O. Westfall, and D. B. Allison. 2003. Years of life lost due to obesity. JAMA 289(2):187–193.

Förster, L. J., M. Vogel, R. Stein, A. Hilbert, J. L. Breinker, M. Böttcher, W. Kiess, and T. Poulain. 2023. Mental health in children and adolescents with overweight or obesity. BMC Public Health 23(1):135.

Fryar, C. D., M. D. Carroll, and J. Afful. 2020. Prevalence of overweight, obesity, and severe obesity among children and adolescents aged 2–19 years: United States, 1963–1965 through 2017–2018. NCHS Health E-Stats, Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/data/hestat/obesity-child-17-18/obesity-child.htm (accessed March 20, 2024).

Gadde, K. M., D. B. Allison, D. H. Ryan, C. A. Peterson, B. Troupin, M. L. Schwiers, and W. W. Day. 2011. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. The Lancet 377(9774): 1341–1352.

Garvey, W. T., J. I. Mechanick, E. M. Brett, A. J. Garber, D. L. Hurley, A. M. Jastreboff, K. Nadolsky, R. Pessah-Pollack, R. Plodkowski, and Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. 2016. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity: Executive summary. Endocrine Practice 22(7):842–884.

Garvey, W. T., J. P. Frias, A. M. Jastreboff, C. W. le Roux, N. Sattar, D. Aizenberg, H. Mao, S. Zhang, N. N. Ahmad, M. C. Bunck, I. Benabbad, X. M. Zhang, and SURMOUNT-2 Investigators. 2023. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 402(10402):613–626.

Genazzani, A. R., and M. Gambacciani. 2006. Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution. Gynecological Endocrinology 22(3):145–150.

Goldschmidt, A. B., J. Khoury, T. M. Jenkins, D. S. Bond, J. G. Thomas, L. M. Utzinger, M. H. Zeller, T. H. Inge, and J. E. Mitchell. 2018. Adolescent loss-of-control eating and weight loss maintenance after bariatric surgery. Pediatrics 141(1):e20171659.

Grannell, A., A. Kokkinos, and C. W. le Roux. 2022. Myokines in appetite control and energy balance. Muscles 1(1):26–47.

Greenblatt, D. J. 2013. The seventy-kilogram fantasy. Clinical Pharmacology in Development 2(2):101–102.

Greenblatt, D. J., J. S. Harmatz, and C. R. Chow. 2018a. Vortioxetine disposition in obesity: Potential implications for patient safety. Journal of Clinical Psychopharmacology 38(3):172–179.

Greenblatt, D. J., J. S. Harmatz, M. J. Ryan, and C. R. Chow. 2018b. Sustained impairment of lurasidone clearance after discontinuation of posaconazole: Impact of obesity, and implications for patient safety. Journal of Clinical Psychopharmacology 38(4):289–295.

Greenblatt, D. J., C. D. Bruno, J. S. Harmatz, Q. Zhang, and C. R. Chow. 2022. Drug disposition in subjects with obesity: The research work of Darrell R. Abernethy. Journal of Clinical Pharmacology 62(11):1350–1363.

Greenway, F. L., K. Fujioka, R. A. Plodkowski, S. Mudaliar, M. Guttadauria, J. Erickson, D. D. Kim, E. Dunayevich, and COR-I Study Group. 2010. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 376(9741):595–605.

Grunvald, E., R. Shah, R. Hernaez, A. K. Chandar, O. Pickett-Blakely, L. M. Teigen, T. Harindhanavudhi, S. Khandelwal, M. M. Jamal, V. R. Muthusamy, S. E. Brewer, H. Hampel, S. Sultan, and Y. Falck-Ytter. 2022. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology 163(5):1198–1225.

Halfon, N., K. Larson, and W. Slusser. 2013. Associations between obesity and comorbid mental health, developmental, and physical health conditions in a nationally representative sample of U.S. children aged 10 to 17. Academic Pediatrics 13(1):6–13.

Hampl, S. E., S. G. Hassink, A. C. Skinner, S. C. Armstrong, S. E. Barlow, C. F. Bolling, K. C. Avila Edwards, I. Eneli, R. Hamre, M. M. Joseph, D. Lunsford, E. Mendonca, M. P. Michalsky, N. Mirza, E. R. Ochoa, Jr., M. Sharifi, A. E. Staiano, A. E. Weedn, S. K. Flinn, J. Lindros, and K. Okechukwu. 2023. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics 151(2):e2022060640.

Huang, S. M., R. Temple, D. C. Throckmorton, and L. J. Lesko. 2007. Drug interaction studies: Study design, data analysis, and implications for dosing and labeling. Clinical Pharmacology & Therapeutics 81(2):298–304.

IOM (Institute of Medicine). 2011. Clinical practice guidelines we can trust. Washington, DC: The National Academies Press.

Iwatate, E., F. D. Atem, E. C. Jones, J. L. Hughes, T. Yokoo, and S. E. Messiah. 2023. Association of obesity, suicide behaviors, and psychosocial wellness among adolescents in the United States. Journal of Adolescent Health 72(4):526–534.

Jakicic, J. M., R. J. Rogers, and T. S. Church. 2024. Physical activity in the new era of anti-obesity medications. Obesity 32(2):234–236.

Jain, R., S. M. Chung, L. Jain, M. Khurana, S. W. Lau, J. E. Lee, J. Vaidyanathan, I. Zadezensky, S. Choe, and C. G. Sahajwalla. 2011. Implications of obesity for drug therapy: Limitations and challenges. Clinical Pharmacology & Therapeutics 90(1):77–89.

Jastreboff, A. M., and R. F. Kushner. 2023. New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics. Annual Review of Medicine 74:125–139.

Jastreboff, A. M., L. J. Aronne, N. N. Ahmad, S. Wharton, L. Connery, B. Alves, A. Kiyosue, S. Zhang, B. Liu, M. C. Bunck, A. Stefanski, and SURMOUNT-1 Investigators. 2022. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine 387(3):205–216.

Jastreboff, A. M., L. M. Kaplan, J. P. Frías, Q. Wu, Y. Du, S. Gurbuz, T. Coskun, A. Haupt, Z. Milicevic, and M. L. Hartman. 2023. Triple-hormone-receptor agonist retatrutide for obesity—A phase 2 trial. New England Journal of Medicine 389(6):514–526.

Jensen, M. D., D. H. Ryan, K. A. Donato, C. M. Apovian, J. D. Ard, A. G. Comuzzie, F. B. Hu, V. S. Hubbard, J. M. Jakicic, R. F. Kushner, C. M. Loria, B. E. Millen, C. A. Nonas, F. X. Pi-Sunyer, J. Stevens, V. J. Stevens, T. A. Wadden, B. M. Wolfe, and S. Z. Yanovski. 2014. Guidelines for managing overweight and obesity in adults. Obesity 22(S2):S1–S410.

Johnson, K. C., G. A. Bray, L. J. Cheskin, J. M. Clark, C. M. Egan, J. P. Foreyt, K. R. Garcia, S. Glasser, F. L. Greenway, E. W. Gregg, H. P. Hazuda, A. Hergenroeder, J. O. Hill, E. S. Horton, J. M. Jakicic, R. W. Jeffery, S. E. Kahn, W. C. Knowler, C. E. Lewis, M. Miller, M. G. Montez, D. M. Nathan, J. L. Patricio, A. L. Peters, X. Pi-Sunyer, H. J. Pownall, D. Reboussin, J. B. Redmon, H. Steinberg, T. A. Wadden, L. E. Wagenknecht, R. R. Wing, C. R. Womack, S. Z. Yanovski, P. Zhang, A. V. Schwartz, and Look AHEAD Study Group. 2017. The effect of intentional weight loss on fracture risk in persons with diabetes: Results from the Look AHEAD randomized clinical trial. Journal of Bone and Mineral Research 32(11):2278–2287.

Johnson-Mann C. N., J. S. Cupka, A. Ro, A. E. Davidson, B. A. Armfield, F. Miralles, A. Markal, K. E. Fierman, V. Hough, M. Newsom, I. Verma, A. V. Dozic, and A. Bihorac. 2023. A systematic review on participant diversity in clinical trials—Have we made progress for the management of obesity and its metabolic sequelae in diet, drug, and surgical trials. Journal of Racial and Ethnic Health Disparities 10(6):3140–3149.

Joszt, L. 2023. FDA approves diabetes drug tirzepatide for chronic weight management. AJMC. https://www.ajmc.com/view/fda-approves-diabetes-drug-tirzepatide-for-chronic-weight-management (accessed March 19, 2024).

Kelly, A. S., P. Auerbach, M. Barrientos-Perez, I. Gies, P. M. Hale, C. Marcus, L. D. Mastrandrea, N. Prabhu, S. Arslanian, and NN8022–4180 Trial Investigators. 2020. A randomized, controlled trial of liraglutide for adolescents with obesity. New England Journal of Medicine 382(22):2117–2128.

Kelly, A. S., M. O. Bensignor, D. S. Hsia, A. H. Shoemaker, W. Shih, C. Peterson, and S. T. Varghese. 2022. Phentermine/topiramate for the treatment of adolescent obesity. NEJM Evidence 1(6):10.1056/evidoa2200014.

Kessler, R. C., P. A. Berglund, W. T. Chiu, A. C. Deitz, J. I. Hudson, V. Shahly, S. AguilarGaxiola, J. Alonso, M. C. Angermeyer, C. Benjet, R. Bruffaerts, G. de Girolamo, R. de Graaf, J. Maria Haro, V. Kovess-Masfety, S. O’Neill, J. Posada-Villa, C. Sasu, K. Scott, M. C. Viana, and M. Xavier. 2013. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biological Psychiatry 73(9):904–914.

Kosiborod, M. N., S. Z. Abildstrøm, B. A. Borlaug, J. Butler, S. Rasmussen, M. Davies, G. K. Hovingh, D. W. Kitzman, M. L. Lindegaard, D. V. Møller, S. J. Shah, M. B. Treppendahl, S. Verma, W. Abhayaratna, F. Z. Ahmed, V. Chopra, J. Ezekowitz, M. Fu, H. Ito, M. Lelonek, V. Melenovsky, B. Merkely, J. Núñez, E. Perna, M. Schou, M. Senni, K. Sharma, P. Van der Meer, D. von Lewinski, D. Wolf, and M. C Petrie, for the STEP-HFpEF Trial Committees and Investigators. 2023. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine 389(12):1069–1084.

Kushner, R. F., and D. H. Ryan. 2014. Assessment and lifestyle management of patients with obesity: Clinical recommendations from systematic reviews. JAMA 312(9):943–952.

Langevin, B., J. V. S. Gobburu, and M. Gopalakrishnan. 2023. Is there a need for a dedicated pharmacokinetic trial for a drug in obese populations? A drug prioritization decision tree framework. Journal of Clinical Pharmacology 63(S2):S48–S64.

Lebow, J., L. A. Sim, and L. N. Kransdorf. 2015. Prevalence of a history of overweight and obesity in adolescents with restrictive eating disorders. Journal of Adolescent Health 56(1):19–24.

le Roux, C. W., O. Steen, K. J. Lucas, E. Startseva, A. Unseld, and A. M. Hennige. 2024. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: A randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology 12(3):162–173.

Lewis, K. H., J. D. Ard, and N. M. Pajewski. 2022. Long-term effectiveness of the antiobesity medication phentermine (LEAP). Identifier NCT05176626. https://clinicaltrials.gov/study/NCT05176626 (accessed March 19, 2024).

Li, J.-R., J. Cao, J. Wei, and W. Geng. 2023. Case report: Semaglutide-associated depression: A report of two cases. Frontiers in Psychiatry 14:1238353.

Lincoff, A. M., K. Brown-Frandsen, H. M. Colhoun, J. Deanfield, S. S. Emerson, S. Esbjerg, S. Hardt-Lindberg, G. K. Hovingh, S. E. Kahn, R. F. Kushner, I. Lingvay, T. K. Oral, M. M. Michelsen, J. Plutzky, C. W. Tornøe, D. H. Ryan, and SELECT Trial Investigators. 2023. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine 389(24):2221–2232.

Lindberg, L., E. Hagman, P. Danielsson, C. Marcus, and M. Persson. 2020. Anxiety and depression in children and adolescents with obesity: A nationwide study in Sweden. BMC Medicine 18(1):30. https://doi.org/10.1186/s12916-020-1498-z.

Look, M. 2024. The new era of anti-obesity medications [Conference presentation]. Washington Obesity Society 2024 Spring Symposium, Tukwila, WA.

Maahs, D., D. G. de Serna, R. L. Kolotkin, S. Ralston, J. Sandate, C. Qualls, and D. S. Schade. 2006. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocrine Practice 12(1):18–28.

Madabushi, R. 2022. Special populations and regulatory considerations in drug development obese patients [Conference presentation]. Bridging Drug Efficacy and Safety to the Obese: Considerations and Scientific Approaches, Maryland, United States. https://cersi.umd.edu/bridging-drug-efficacy-and-safety-obese-considerations-and-scientific-approaches (accessed March 19, 2024)

Mendieta-Zerón, H., M. López, and C. Diéguez. 2008. Gastrointestinal peptides controlling body weight homeostasis. General and Comparative Endocrinology 155(3):481–495.

Mitchison, D., J. Mond, K. Bussey, S. Griffiths, N. Trompeter, A. Lonergan, K. M. Pike, S. B. Murray, and P. Hay. 2020. DSM-5 full syndrome, other specified, and unspecified eating disorders in Australian adolescents: Prevalence and clinical significance. Psychological Medicine 50(6):981–990.

Morgan-Bathke, M., S. D. Baxter, T. M. Halliday, A. Lynch, N. Malik, H. A. Raynor, J. L. Garay, and M. Rozga. 2023. Weight management interventions provided by a dietitian for adults with overweight or obesity: An evidence analysis center systematic review and meta-analysis. Journal of the Academy of Nutrition and Dietetics 123(11):1621–1661.e25.

Müller, T. D., M. Blüher, M. H. Tschöp, and R. D. DiMarchi. 2022. Anti-obesity drug discovery: Advances and challenges. Nature Reviews Drug Discovery 21(3):201–223.

NHLBI (National Heart, Lung, and Blood Institute). 2013. Managing overweight and obesity in adults: Systematic evidence review from the obesity expert panel. 2013. National Institutes of Health. https://internet-prod.nhlbi.nih.gov/sites/default/files/media/docs/obesity-evidence-review.pdf (accessed March 20, 2024).

NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults. 1998. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. Bethesda, MD: National Heart, Lung, and Blood Institute.

Nicol, G., E. Worsham, D. Haire-Joshu, A. Duncan, J. Schweiger, M. Yingling, and E. Lenze. 2016. Getting to more effective weight management in antipsychotic-treated youth: A survey of barriers and preferences. Childhood Obesity 12(1):70–76.

NLM (National Library of Medicine). 2019. A research study on how well semaglutide helps children and teenagers with excess body weight lose weight (STEP Young). Identifier NCT05726227. https://clinicaltrials.gov/study/NCT05726227 (accessed March 19, 2024).

Office of Clinical Pharmacology. 2023. Good review practices: Clinical pharmacology review of new molecular entity (NME) new drug applications (NDAs) and original biologics license applications (BLAs). (MAPP 4000.4 Rev.1). U.S. Food and Drug Administration. https://www.fda.gov/media/71709/download (accessed March 19, 2024).

Office of New Drugs. 2013. Good review practice: Clinical review of investigational new drug applications. U.S. Food and Drug Administration. https://www.fda.gov/media/87621/download (accessed March 19, 2024).

Ogden, C. L., M. D. Carroll, C. D. Fryar, and K. M. Flegal. 2015. Prevalence of obesity among adults and youth: United States, 2011–2014 (NCHS Data Brief No. 219). National Center for Health Statistics. https://www.cdc.gov/nchs/data/databriefs/db219.pdf (accessed March 19, 2024).

Onakpoya, I. J., C. J. Heneghan, and J. K. Aronson. 2016. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: A systematic review. BMC Medicine (14):191.

Orgel, E., R. Sposto, J. Malvar, N. L. Seibel, E. Ladas, P. S. Gaynon, and D. R. Freyer. 2014. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children’s Oncology Group. Journal of Clinical Oncology 32(13):1331–1337.

Pan, X., L. Wang, J. Liu, J. C. Earp, Y. Yang, J. Yu, F. Li, Y. Bi, A. Bhattaram, and H. Zhu. 2023. Model-informed approaches to support drug development for patients with obesity: A regulatory perspective. Journal of Clinical Pharmacology 63(S2): S65–S77.

Pestine, E., A. Stokes, and L. Trinquart. 2018. Representation of obese participants in obesity-related cancer randomized trials. Annals of Oncology 29(7):1582–1587.

Pi-Sunyer, X., A. Astrup, K. Fujioka, F. Greenway, A. Halpern, M. Krempf, D. C. Lau, C. W. le Roux, R. Violante Ortiz, C. B. Jensen, J. P. Wilding, and SCALE Obesity and Prediabetes NN8022-1839 Study Group. 2015. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 373(1):11–22.

Pilitsi, E., O. M. Farr, S. A. Polyzos, N. Perakakis, E. Nolen-Doerr, A. E. Papathanasiou, and C. S. Mantzoros. 2019. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism 92:170–192.

Pillinger, T., R. A. McCutcheon, L. Vano, Y. Mizuno, A. Arumuham, G. Hindley, K. Beck, S. Natesan, O. Efthimiou, A. Cipriani, and O. D. Howes. 2020. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis. The Lancet Psychiatry 7(1):64–77.

Ramamoorthy, A., R. Araojo, K. P. Vasisht, M. Fienkeng, D. J. Green, and R. Madabushi. 2023. Promoting clinical trial diversity: A highlight of select U.S. FDA initiatives. Clinical Pharmacology & Therapeutics 113(3):528–535.

Raynor, H. A., M. Morgan-Bathke, S. D. Baxter, T. Halliday, A. Lynch, N. Malik, J. L. Garay, and M. Rozga. 2024. Position of the Academy of Nutrition and Dietetics: Medical nutrition therapy behavioral interventions provided by dietitians for adults with overweight or obesity, 2024. Journal of the Academy of Nutrition and Dietetics 124(3):408–415.

Richards, J., N. Bang, E. L. Ratliff, M. A. Paszkowiak, Z. Khorgami, S. S. Khalsa and W. K. Simmons. 2023. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study. Obesity Pillars (7):e100080.

Richards, J. R., and S. S. Khalsa. 2024. Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss. Obesity Reviews 25(5):e13709.

Rosenfeld, R. M., R. N. Shiffman, and P. Robertson. 2013. Clinical practice guideline development manual, third edition: A quality-driven approach for translating evidence into action. Otolaryngology—Head and Neck Surgery 148(1):S1–S55.

Rubino, D., N. Abrahamsson, M. Davies, D. Hesse, F. L. Greenway, C. Jensen, I. Lingvay, O. Mosenzon, J. Rosenstock, M. A. Rubio, G. Rudofsky, S. Tadayon, T. A. Wadden, D. Dicker, and STEP 4 Investigators. 2021. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA 325(14):1414–1425.

Samuels, S., V. Bhatt-Mehta, K. Park, and G. J. Burckart. 2023. Obesity considerations in pediatric drug development, 2016–2021. Journal of Clinical Pharmacology 63(2): S18–S24.

Scott, K. M., R. Bruffaerts, G. E. Simon, J. Alonso, M. Angermeyer, G. de Girolamo, K. Demyttenaere, I. Gasquet, J. M. Haro, E. Karam, R. C. Kessler, D. Levinson, M. E. Medina Mora, M. A. Oakley Browne, J. Ormel, J. P. Villa, H. Uda, and M. Von Korff. 2008a. Obesity and mental disorders in the general population: Results from the World Mental Health Surveys. International Journal of Obesity 32(1):192–200.

Scott, K. M., M. A. McGee, J. E. Wells, and M. A. Oakley Browne. 2008b. Obesity and mental disorders in the adult general population. Journal of Psychosomatic Research 64(1):97–105.

Shrivastava, A., and M. E. Johnston. 2010. Weight-gain in psychiatric treatment: Risks, implications, and strategies for prevention and management. Mens Sana Monographs 8(1):53–68.

Sim, L. A., J. Lebow, and M. Billings. 2013. Eating disorders in adolescents with a history of obesity. Pediatrics 132(4):e1026–e1030.

Simon, G. E., M. Von Korff, K. Saunders, D. L. Miglioretti, P. K. Crane, G. van Belle, and R. C. Kessler. 2006. Association between obesity and psychiatric disorders in the U.S. adult population. Archives of General Psychiatry 63(7):824–830.

Skinner, A. C., S. N. Ravanbakht, J. A. Skelton, E. M. Perrin, and S. C. Armstrong. 2018. Prevalence of obesity and severe obesity in U.S. children, 1999–2016. Pediatrics 141(3):e20173459.

Swagel, P. 2023. A call for new research in the area of obesity. Congressional Budget Office. https://www.cbo.gov/publication/59590 (accessed March 19, 2024).

Tanner, A. B. 2023. Unique considerations for the medical care of restrictive eating disorders in children and young adolescents. Journal of Eating Disorders 11(33).

Tisdale, M. J. 2010. Reversing cachexia. Cell 142(4):511–512.

Tondt, J., M. Freshwater, S. Benson-Davies, C. Dawkins, J. Magee, S. Karjoo, S. O. Ortiz Page, H. Pile, N. Khan, M. Hurtado Andrade, A. Rajpal, A. Petcu, J. Antoun, H. Haq, E. Fryoux, K. Gugnani, M. Manek, M. P. Aranas, and S. Afreen. 2024. Obesity Algorithm. Obesity Medicine Association. https://obesitymedicine.org/resources/obesity-algorithm/ (accessed March 19, 2024).

USPSTF (U.S. Preventive Services Task Force), D. C. Grossman, K. Bibbins-Domingo, S. J. Curry, M. J. Barry, K. W. Davidson, C. A. Doubeni, J. W. Epling, Jr., A. R. Kemper, A. H. Krist, A. E. Kurth, C. S. Landefeld, C. M. Mangione, M. G. Phipps, M. Silverstein, M. A. Simon, and C. W. Tseng. 2017. Screening for obesity in children and adolescents: U.S. Preventive Services Task Force recommendation statement. JAMA 317(23), 2417–2426.

Vaidyanathan J., E. P. Fletcher, A. Ramamoorthy, R. Madabushi, and G. J. Burckart. 2023. Inclusion of subjects who are obese in drug development: Current status and opportunities. Journal of Clinical Pharmacology 63(2):S10–S17.

Vaughns, J. D., L. S. Conklin, Y. Long, P. Zheng, F. Faruque, D. J. Green, J. N. van den Anker, and G. J. Burckart. 2018. Obesity and pediatric drug development. Journal of Clinical Pharmacology 58(5):650–661.

Wadden, T. A., J. P. Foreyt, G. D. Foster, J. O. Hill, S. Klein, P. M. O’Neil, M. G. Perri, F. X. Pi-Sunyer, C. L. Rock, J. S. Erickson, H. N. Maier, D. D. Kim, and E. Dunayevich. 2011. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity (1):110–120.

Wadden, T. A., P. Hollander, S. Klein, K. Niswender, V. Woo, P. M. Hale, and L. Aronne. 2013. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. International Journal on Obesity (11):1443–51.

Wadden, T. A., T. S. Bailey, L. K. Billings, M. Davies, J. P. Frias, A. Koroleva, I. Lingvay, P. M. O’Neil, D. M. Rubino, D. Skovgaard, S. O. R. Wallenstein, W. T. Garvey, and STEP 3 Investigators. 2021. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA (14):1403–1413.

Wadden, T. A., A. M. Chao, S. Machineni, R. Kushner, J. Ard, G. Srivastava, B. Halpern, S. Zhang, J. Chen, M. C. Bunck, N. N. Ahmad, and T. Forrester. 2023. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The SURMOUNT-3 phase 3 trial. Nature Medicine (11):2909–2918.

Wang, W., N. D. Volkow, N. A. Berger, P. B. Davis, D. C. Kaelber, and R. Xu. 2024. Association of semaglutide with risk of suicidal ideation in a real-world cohort. National Medicine 30(1):168–176.

Weghuber, D., T. Barrett, M. Barrientos-Pérez, I. Gies, D. Hesse, O. K. Jeppesen, A. S. Kelly, L. D. Mastrandrea, R. Sørrig, S. Arslanian, and STEP TEENS Investigators. 2022. Once-weekly semaglutide in adolescents with obesity. New England Journal of Medicine 387(24):2245–2257.

Wharton, S., D. C. W. Lau, M. Vallis, A. M. Sharma, L. Biertho, D. Campbell-Scherer, K. Adamo, A. Alberga, R. Bell, N. Boulé, E. Boyling, J. Brown, B. Calam, C. Clarke, L. Crowshoe, D. Divalentino, M. Forhan, Y. Freedhoff, M. Gagner, S. Glazer, C. Grand, M. Green, M. Hahn, R. Hawa, R. Henderson, D. Hong, P. Hung, I. Janssen, K. Jacklin, C. Johnson-Stoklossa, A. Kemp, S. Kirk, J. Kuk, M. F. Langlois, S. Lear, A. McInnes, D. Macklin, L. Naji, P. Manjoo, M. P. Morin, K. Nerenberg, I. Patton, S. Pedersen, L. Pereira, H. Piccinini-Vallis, M. Poddar, P. Poirier, D. Prud’homme, X. R. Salas, C. Rueda-Clausen, S. Russell-Mayhew, J. Shiau, D. Sherifali, J. Sievenpiper, S. Sockalingam, V. Taylor, E. Toth, L. Twells, R. Tytus, S. Walji, L. Walker, and S. Wicklum. 2020. Obesity in adults: A clinical practice guideline. CMAJ 192(31):E875–E891.

White, G. E., R. E. Boles, A. P. Courcoulas, S. Z. Yanovski, M. H. Zeller, T. M. Jenkins, and T. H. Inge. 2023. A prospective cohort of alcohol use and alcohol-related problems before and after metabolic and bariatric surgery in adolescents. Annals of Surgery 278(3):e519–e525.

Wilding, J. P. H., R. L. Batterham, S. Calanna, M. Davies, L. F. Van Gaal, I. Lingvay, B. M. McGowan, J. Rosenstock, M. T. D. Tran, T. A. Wadden, S. Wharton, K. Yokote, N. Zeuthen, and R. F. Kushner. 2021. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 384(11):989–1002.

Wilfley, D. E., R. I. Stein, B. E. Saelens, D. S. Mockus, G. E. Matt, H. A. Hayden-Wade, R. R. Welch, K. B. Schechtman, P. A. Thompson, and L. H. Epstein. 2007. Efficacy of maintenance treatment approaches for childhood overweight: A randomized controlled trial. JAMA 298(14):1661–73.

Wilfley, D. E., B. E. Saelens, and R. I. Stein. 2017. Dose, content, and mediators of family-based treatment for childhood obesity: A multisite randomized clinical trial. JAMA Pediatric 171(12):1151–1159.

Williams, D., E. Chaves, E. McKnight, and I. Eneli. 2020. Diagnostic and treatment challenges of eating disorders after adolescent bariatric surgery: A case report. Clinical Obesity 10(4):e12367.

Yang, Y. C., C. E. Walsh, M. P. Johnson, D. W. Belsky, M. Reason, P. Curran, A. E. Aiello, M. Chanti-Ketterl, and K. M. Harris. 2021. Life-course trajectories of body mass index from adolescence to old age: Racial and educational disparities. Proceedings of the National Academy of Sciences 118(17):e2020167118.

Yu, J. H., and M. S. Kim. 2012. Molecular mechanisms of appetite regulation. Diabetes & Metabolism Journal 36(6):391–398.